All articles by Vidya Sagar Maddela
Vidya Sagar Maddela
Astellas secures exclusive rights to develop Evopoint’s XNW27011
Astellas will develop and commercialise XNW27011 worldwide, excluding mainland China, Hong Kong, Macao, and Taiwan, in exchange for a $130m upfront payment and up to $1.34bn in milestone payments
Cellares, Mitsui Fudosan open cell therapy Smart Factory in Japan
Located in Kashiwa City, Chiba Prefecture, the new facility aims to address the urgent need for scalable and cost-effective CAR-T cell therapies in Japan and neighbouring regions
Alvotech, Advanz Pharma expand biosimilar partnership in Europe
The agreement builds on their existing partnership, which focuses on enhancing their biosimilar portfolio in Europe, and covers biosimilars to Ilaris (canakinumab), Kesimpta (ofatumumab), and an undisclosed early-stage candidate
Alcon receives FDA approval for Tryptyr to treat dry eye disease
Tryptyr is a first-in-class TRPM8 receptor agonist that rapidly stimulates natural tear production, providing a new option for patients suffering from the multifactorial condition.
Lilly to acquire SiteOne Therapeutics to expand pain pipeline
The acquisition will expand Lilly’s pain management pipeline, featuring STC-004, a Phase 2 ready Nav1.8 inhibitor, which may offer a non-opioid solution for chronic pain patients.
Biogen, City Therapeutics partner to advance RNAi therapies
City Therapeutics will use its advanced RNAi engineering to develop an RNAi trigger molecule, which will be paired with Biogen’s proprietary drug delivery technology.
Shanghai Henlius Biotechsecures EU orphan drug status for HLX22
The Phase 3 HLX22-GC-301 clinical study is assessing the efficacy and safety of HLX22 in combination with trastuzumab and chemotherapy for first-line treatment of HER2-positive metastatic gastric cancer
Lupin taps SteinCares to supply ranibizumab in Latin America
SteinCares will assume the responsibility for regulatory filings, registrations, and commercialisation of the biosimilar in the region, while Lupin will manage the manufacturing process
Abbisko Therapeutics Receives CDE Approval of Breakthrough Therapy Designation for Irpagratinib (ABSK011) in the Treatment of HCC
Patients with advanced or unresectable HCC currently lack effective treatment options following treatment with ICI- and mTKI-based therapies.
Astellas, Pfizer’s Xtandi shows long-term benefits in prostate cancer
Xtandi, the androgen receptor inhibitor, when combined with androgen deprivation therapy (ADT), showed a 30% reduction in the risk of death compared to placebo plus ADT